GBA
Gemeinsamer
Bundesausschuss

Resolution

of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive:
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Belantamab mafodotin (multiple myeloma, relapsed or refractory, after at least one prior therapy, in combination with pomalidomide and dexamethasone)

of 1 October 2026

At their session on 1 October 2026, the Federal Joint Committee (GBA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

I. In Annex XII, the following information shall be added after number 4 to the information on the benefit assessment of Belantamab mafodotin in accordance with the resolution of 1 October 2026 (multiple myeloma, relapsed or refractory, after at least one prior therapy, in combination with bortezomib and dexamethasone):

Courtesy translation – only the German version is legally binding.

Belantamab mafodotin

Resolution of: 1 October 2026
Entry into force on: 1 October 2026
Federal Gazette, BAnz AT DD. MM YYYY Bx

Therapeutic indication (according to the marketing authorisation of 23 July 2026):

Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.

Therapeutic indication of the resolution (resolution of 1 October 2026):

See therapeutic indication according to marketing authorisation.

1. Additional benefit of the medicinal product in relation to the appropriate comparator therapy

a) Adults with relapsed or refractory multiple myeloma who have received one to three prior therapies; pretreatment includes lenalidomide

Appropriate comparator therapy:

An individualised therapy with the selection of

- carfilzomib in combination with lenalidomide and dexamethasone,
- elotuzumab in combination with lenalidomide and dexamethasone,
- elotuzumab in combination with pomalidomide and dexamethasone (only subjects who have received at least two prior therapies and have shown disease progression during the last therapy are eligible),
- daratumumab in combination with bortezomib and dexamethasone,
- daratumumab in combination with lenalidomide and dexamethasone,
- daratumumab in combination with carfilzomib and dexamethasone,
- daratumumab in combination with pomalidomide and dexamethasone (only subjects who are refractory to lenalidomide or have received at least two prior therapies are eligible),
- isatuximab in combination with carfilzomib and dexamethasone,
- isatuximab in combination with pomalidomide and dexamethasone (only subjects who have received at least two prior therapies and have shown disease progression during the last therapy are eligible),
- pomalidomide in combination with bortezomib and dexamethasone (only subjects who are refractory to an anti-CD38 antibody and lenalidomide are eligible),
- ixazomib in combination with lenalidomide and dexamethasone (only subjects who are refractory to bortezomib, carfilzomib and an anti-CD38 antibody are eligible) and
- carfilzomib in combination with dexamethasone

Courtesy translation – only the German version is legally binding.

Extent and probability of the additional benefit of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with the appropriate comparator therapy:

An additional benefit is not proven.

b) Adults with relapsed or refractory multiple myeloma who have received at least four prior therapies; pretreatment includes lenalidomide

Appropriate comparator therapy:

An individualised therapy with the selection of

- carfilzomib in combination with lenalidomide and dexamethasone,
- elotuzumab in combination with lenalidomide and dexamethasone,
- elotuzumab in combination with pomalidomide and dexamethasone (only subjects who have shown disease progression during the last therapy are eligible),
- daratumumab in combination with bortezomib and dexamethasone,
- daratumumab in combination with lenalidomide and dexamethasone,
- daratumumab in combination with carfilzomib and dexamethasone,
- daratumumab in combination with pomalidomide and dexamethasone,
- isatuximab in combination with carfilzomib and dexamethasone,
- isatuximab in combination with pomalidomide and dexamethasone (only subjects who have shown disease progression during the last therapy are eligible),
- pomalidomide in combination with bortezomib and dexamethasone (only subjects who are refractory to an anti-CD38 antibody and lenalidomide are eligible),
- ixazomib in combination with lenalidomide and dexamethasone (only subjects who are refractory to bortezomib, carfilzomib and an anti-CD38 antibody are eligible),
- carfilzomib in combination with dexamethasone,
- panobinostat in combination with bortezomib and dexamethasone,
- pomalidomide in combination with dexamethasone (only at least double-refractory subjects, who are ineligible for triplet therapy and have shown disease progression during the last therapy, are eligible),
- lenalidomide in combination with dexamethasone (only at least double-refractory subjects, who are ineligible for triplet therapy, are eligible),
- bortezomib in combination with pegylated liposomal doxorubicin (only at least double-refractory subjects, who are ineligible for triplet therapy, are eligible),
- bortezomib in combination with dexamethasone (only at least double-refractory subjects, who are ineligible for triplet therapy, are eligible),
- daratumumab monotherapy (only at least triple-refractory subjects, who are ineligible for triplet or doublet therapy, are eligible),
- cyclophosphamide as monotherapy or in combination with dexamethasone (only at least triple-refractory subjects, who are ineligible for triplet or doublet therapy, are eligible) and

Courtesy translation – only the German version is legally binding.

- melphalan as monotherapy or in combination with prednisolone or prednisone (only at least triple-refractory subjects, who are ineligible for triplet or doublet therapy, are eligible).

Extent and probability of the additional benefit of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with the appropriate comparator therapy:

An additional benefit is not proven.

Study results according to endpoints:[1]

a) Adults with relapsed or refractory multiple myeloma who have received one to three prior therapies; pretreatment includes lenalidomide

There are no assessable data.

Summary of results for relevant clinical endpoints

Endpoint category	Direction of effect/ risk of bias	Summary
Mortality	n.a.	There are no assessable data.
Morbidity	n.a.	There are no assessable data.
Health-related quality of life	n.a.	There are no assessable data.
Side effects	n.a.	There are no assessable data.
Explanations: ↑: statistically significant and relevant positive effect with low/unclear reliability of data ↓: statistically significant and relevant negative effect with low/unclear reliability of data ↑↑: statistically significant and relevant positive effect with high reliability of data ↓↓: statistically significant and relevant negative effect with high reliability of data ↔: no statistically significant or relevant difference ∅: No data available. n.a.: not assessable		

[1] Data from the dossier assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) (A26-39) unless otherwise indicated.

Courtesy translation – only the German version is legally binding.

b) Adults with relapsed or refractory multiple myeloma who have received at least four prior therapies; pretreatment includes lenalidomide

There are no assessable data.

Summary of results for relevant clinical endpoints

Endpoint category	Direction of effect/ risk of bias	Summary
Mortality	n.a.	There are no assessable data.
Morbidity	n.a.	There are no assessable data.
Health-related quality of life	n.a.	There are no assessable data.
Side effects	n.a.	There are no assessable data.
Explanations: ↑: statistically significant and relevant positive effect with low/unclear reliability of data ↓: statistically significant and relevant negative effect with low/unclear reliability of data ↑↑: statistically significant and relevant positive effect with high reliability of data ↓↓: statistically significant and relevant negative effect with high reliability of data ↔: no statistically significant or relevant difference ∅: No data available. n.a.: not assessable		

2. Number of patients or demarcation of patient groups eligible for treatment

a) Adults with relapsed or refractory multiple myeloma who have received one to three prior therapies; pretreatment includes lenalidomide

Approximately 1,880 to 2,350 patients

b) Adults with relapsed or refractory multiple myeloma who have received at least four prior therapies; pretreatment includes lenalidomide

Approximately 1,100 to 1,180 patients

3. Requirements for a quality-assured application

The requirements in the product information are to be taken into account. The European Medicines Agency (EMA) provides the contents of the product information (summary of product characteristics, SmPC) for Blenrep (active ingredient: belantamab mafodotin) at the following publicly accessible link (last access: 1 July 2026):

https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf

Treatment with belantamab mafodotin should only be initiated and monitored by specialists in internal medicine, haematology and oncology experienced in the treatment of patients with multiple myeloma.

Courtesy translation – only the German version is legally binding.

In accordance with the EMA requirements regarding additional risk minimisation measures, the pharmaceutical company must provide training material that contains information for medical professionals and patients (including patient identification card).

The training material contains, in particular, information and warnings about ocular (eye-related) side effects. The training material explains how to carry out eye examinations and contains information on the treatment and prevention of ocular side effects.

4. Treatment costs

Annual treatment costs:

The annual treatment costs shown refer to the first year of treatment.

a) Adults with relapsed or refractory multiple myeloma who have received one to three prior therapies; pretreatment includes lenalidomide

Designation of the therapy	Annual treatment costs/ patient
Medicinal product to be assessed:	
Belantamab mafodotin in combination with pomalidomide and dexamethasone	
Belantamab mafodotin	€ 70,793.44 – € 152,242.96
Pomalidomide	€ 24,755.77
Dexamethasone	€ 194.52
Total	€ 95,743.73 – € 177,193.25
Additionally required SHI services	€ 10.49
Appropriate comparator therapy:	
An individualised therapy with the selection of	
Carfilzomib in combination with lenalidomide and dexamethasone	
Carfilzomib	€ 80,095.58
Lenalidomide	€ 467.78
Dexamethasone	€ 194.52
Total	€ 80,757.88
Additionally required SHI services	€ 10.49
Elotuzumab in combination with lenalidomide and dexamethasone	
Elotuzumab	€ 88,274.40
Lenalidomide	€ 467.78
Dexamethasone	€ 187.08
Total	€ 88,929.28
Additionally required SHI services	€ 284.80 – € 289.10
Elotuzumab in combination with pomalidomide and dexamethasone (only subjects who have received at least two prior therapies and have shown disease progression during the last therapy are eligible)	

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Annual treatment costs/ patient
Elotuzumab	€ 88,274.40
Pomalidomide	€ 24,755.77
Dexamethasone	€ 189.81
Total	€ 113,219.98
Additionally required SHI services	€ 184.21 – € 186.94
Daratumumab in combination with bortezomib and dexamethasone	
Daratumumab	€ 116,967.06
Bortezomib	€ 5,635.52
Dexamethasone	€ 149.30
Total	€ 122,751.88
Additionally required SHI services	€ 210.41 – € 213.42
Daratumumab in combination with lenalidomide and dexamethasone	
Daratumumab	€ 128,106.78
Lenalidomide	€ 467.78
Dexamethasone	€ 108.48
Total	€ 128,683.04
Additionally required SHI services	€ 261.25 – € 264.55
Daratumumab in combination with carfilzomib and dexamethasone	
Daratumumab	€ 128,106.78
Carfilzomib	€ 151,236.12
Dexamethasone	€ 175.53
Total	€ 279,518.43
Additionally required SHI services	€ 232.21 – € 235.51
Daratumumab in combination with pomalidomide and dexamethasone (only subjects who are refractory to lenalidomide or have received at least two prior therapies are eligible)	
Daratumumab	€ 128,106.78
Pomalidomide	€ 24,755.77
Dexamethasone	€ 108.48
Total	€ 152,971.03
Additionally required SHI services	€ 261.25 – € 264.55
Isatuximab in combination with carfilzomib and dexamethasone	
Isatuximab	€ 67,648.84
Carfilzomib	€ 151,236.12
Dexamethasone	€ 245.19
Total	€ 219,130.15

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Annual treatment costs/ patient
Isatuximab in combination with pomalidomide and dexamethasone (only subjects who have received at least two prior therapies and have shown disease progression during the last therapy are eligible)	
Isatuximab	€ 67,648.84
Pomalidomide	€ 24,755.77
Dexamethasone	€ 194.52
Total	€ 92,599.13
Additionally required SHI services	€ 10.49
Pomalidomide in combination with bortezomib and dexamethasone (only subjects who are refractory to an anti-CD38 antibody and lenalidomide are eligible)	
Pomalidomide	€ 22,089.76
Bortezomib	€ 8,946.39
Dexamethasone	€ 239.53
Total	€ 31,275.68
Additionally required SHI services	€ 10.49
Ixazomib in combination with lenalidomide and dexamethasone (only subjects who are refractory to bortezomib, carfilzomib and an anti-CD38 antibody are eligible)	
Ixazomib	€ 78,861.90
Lenalidomide	€ 467.78
Dexamethasone	€ 194.52
Total	€ 79,524.20
Additionally required SHI services	€ 10.49
carfilzomib in combination with dexamethasone	
Carfilzomib	€ 151,236.12
Dexamethasone	€ 245.19
Total	€ 151,481.31

Costs after deduction of statutory rebates (LAUER-TAXE® as last revised: 15 July 2026)

Courtesy translation – only the German version is legally binding.

Other SHI services:

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Medicinal product to be assessed					
Belantamab mafodotin in combination with pomalidomide and dexamethasone					
Belantamab mafodotin	Surcharge for the preparation of parenteral solutions containing Belantamab mafodotin	€ 100	1	7.0 – 13.0	€ 700 – € 1,300
Appropriate comparator therapy					
Carfilzomib in combination with lenalidomide and dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1st - 12th cycle: 6 From 13th cycle: 4	76.0	€ 7,600
Elotuzumab in combination with lenalidomide and dexamethasone					
Elotuzumab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	1st - 2nd cycle: 4 From 3rd cycle: 2	30.0	€ 3,000
Elotuzumab in combination with pomalidomide and dexamethasone					
Elotuzumab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	1st - 2nd cycle: 4 From 3rd cycle: 1	19.0	€ 1,900
Daratumumab in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a	€ 100	4	32.0	€ 3,200

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
	parenteral preparation containing cytostatic agents				
Daratumumab in combination with carfilzomib and dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	6	78.0	€ 7,800
Isatuximab in combination with carfilzomib and dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	6	78.0	€ 7,800
Pomalidomide in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1st - 8th cycle: 4 From 9th cycle: 2	50.8	€ 5,080
Carfilzomib in combination with dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	6	78.0	€ 7,800

Courtesy translation – only the German version is legally binding.

b) Adults with relapsed or refractory multiple myeloma who have received at least four prior therapies; pretreatment includes lenalidomide

Designation of the therapy	Annual treatment costs/ patient
Medicinal product to be assessed:	
Belantamab mafodotin in combination with pomalidomide and dexamethasone	
Belantamab mafodotin	€ 70,793.44 – € 152,242.96
Pomalidomide	€ 24,755.77
Dexamethasone	€ 194.52
Total	€ 95,743.73 – € 177,193.25
Additionally required SHI services	€ 10.49
Appropriate comparator therapy:	
An individualised therapy with the selection of	
Carfilzomib in combination with lenalidomide and dexamethasone	
Carfilzomib	€ 80,095.58
Lenalidomide	€ 467.78
Dexamethasone	€ 194.52
Total	€ 80,757.88
Additionally required SHI services	€ 10.49
Elotuzumab in combination with lenalidomide and dexamethasone	
Elotuzumab	€ 88,274.40
Lenalidomide	€ 467.78
Dexamethasone	€ 187.08
Total	€ 88,929.28
Additionally required SHI services	€ 284.80 – € 289.10
Elotuzumab in combination with pomalidomide and dexamethasone (only subjects who have shown disease progression during the last therapy are eligible)	
Elotuzumab	€ 88,274.40
Pomalidomide	€ 24,755.77
Dexamethasone	€ 189.81
Total	€ 113,219.98
Additionally required SHI services	€ 184.21 – € 186.94
Daratumumab in combination with bortezomib and dexamethasone	
Daratumumab	€ 116,967.06
Bortezomib	€ 5,635.52
Dexamethasone	€ 149.30
Total	€ 122,751.88
Additionally required SHI services	€ 210.41 – € 213.42

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Annual treatment costs/ patient
Daratumumab in combination with lenalidomide and dexamethasone	
Daratumumab	€ 128,106.78
Lenalidomide	€ 467.78
Dexamethasone	€ 108.48
Total	€ 128,683.04
Additionally required SHI services	€ 261.25 – € 264.55
Daratumumab in combination with carfilzomib and dexamethasone	
Daratumumab	€ 128,106.78
Carfilzomib	€ 151,236.12
Dexamethasone	€ 175.53
Total	€ 279,518.43
Additionally required SHI services	€ 232.21 – € 235.51
Daratumumab in combination with pomalidomide and dexamethasone	
Daratumumab	€ 128,106.78
Pomalidomide	€ 24,755.77
Dexamethasone	€ 108.48
Total	€ 152,971.03
Additionally required SHI services	€ 261.25 – € 264.55
Isatuximab in combination with carfilzomib and dexamethasone	
Isatuximab	€ 67,648.84
Carfilzomib	€ 151,236.12
Dexamethasone	€ 245.19
Total	€ 219,130.15
Isatuximab in combination with pomalidomide and dexamethasone (only subjects who have shown disease progression during the last therapy are eligible)	
Isatuximab	€ 67,648.84
Pomalidomide	€ 24,755.77
Dexamethasone	€ 194.52
Total	€ 92,599.13
Additionally required SHI services	€ 10.49
Pomalidomide in combination with bortezomib and dexamethasone (only subjects who are refractory to an anti-CD38 antibody and lenalidomide are eligible)	
Pomalidomide	€ 22,089.76
Bortezomib	€ 8,946.39
Dexamethasone	€ 239.53
Total	€ 31,275.68
Additionally required SHI services	€ 10.49

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Annual treatment costs/ patient
Ixazomib in combination with lenalidomide and dexamethasone (only subjects who are refractory to bortezomib, carfilzomib and an anti-CD38 antibody are eligible)	
Ixazomib	€ 78,861.90
Lenalidomide	€ 467.78
Dexamethasone	€ 194.52
Total	€ 79,524.20
Additionally required SHI services	€ 10.49
Carfilzomib in combination with dexamethasone	
Carfilzomib	€ 151,236.12
Dexamethasone	€ 245.19
Total	€ 151,481.31
Panobinostat in combination with bortezomib and dexamethasone	
Panobinostat	€ 37,243.28 - € 74,486.56
Bortezomib	€ 5,635.52 – € 8,453.28
Dexamethasone	€ 170.97 – € 235.76
Total	€ 43,049.77 – € 83,175.60
Pomalidomide in combination with dexamethasone (only at least double-refractory subjects, who are ineligible for triplet therapy and have shown disease progression during the last therapy, are eligible)	
Pomalidomide	€ 24,755.77
Dexamethasone	€ 194.52
Total	€ 24,950.29
Additionally required SHI services	€ 10.49
Lenalidomide in combination with dexamethasone (only at least double-refractory subjects, who are ineligible for triplet therapy, are eligible)	
Lenalidomide	€ 467.78
Dexamethasone	€ 314.23
Total	€ 782.01
Additionally required SHI services	€ 10.49
Bortezomib in combination with pegylated liposomal doxorubicin (only at least double-refractory subjects, who are ineligible for triplet therapy, are eligible)	
Bortezomib	€ 5,635.52
Doxorubicin (pegylated, liposomal)	€ 17,470.64
Total	€ 23,106.16
Bortezomib in combination with dexamethasone (only at least double-refractory subjects, who are ineligible for triplet therapy, are eligible)	
Bortezomib	€ 2,817.76 – € 5,635.52
Dexamethasone	€ 106.18 – € 170.97

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Annual treatment costs/ patient
Total	€ 2,923.94 – € 5,806.49
Daratumumab monotherapy (only at least triple-refractory subjects, who are ineligible for triplet or doublet therapy, are eligible)	
Daratumumab	€ 128,106.78
Additionally required SHI services	€ 326.79 – € 600.19
Cyclophosphamide as monotherapy (only at least triple-refractory subjects, who are ineligible for triplet or doublet therapy, are eligible)	
Cyclophosphamide	€ 567.50 – € 5,492.89
Cyclophosphamide in combination with dexamethasone (only at least triple-refractory subjects, who are ineligible for triplet or doublet therapy, are eligible)	
Cyclophosphamide	Not calculable
Dexamethasone	Not calculable
Total	Not calculable
Melphalan as monotherapy (only at least triple-refractory subjects, who are ineligible for triplet or doublet therapy, are eligible)	
Melphalan	€ 615.29
Melphalan in combination with prednisolone or prednisone (only at least triple refractory subjects, who are ineligible for triplet or doublet therapy, are eligible)	
Melphalan	€ 411.77 – € 615.29
Prednisone	€ 135.98 – € 203.19
Total	€ 547.75 – € 818.48
Prednisolone	€ 65.15 – € 97.35
Total	€ 476.92 – € 712.64

Costs after deduction of statutory rebates (LAUER-TAXE® as last revised: 15 July 2026)

Other SHI services:

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Medicinal product to be assessed					
Belantamab mafodotin in combination with pomalidomide and dexamethasone					
Belantamab mafodotin	Surcharge for the preparation of parenteral solutions containing Belantamab mafodotin	€ 100	1	7.0 – 13.0	€ 700 – € 1,300

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Appropriate comparator therapy					
Carfilzomib in combination with lenalidomide and dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1st – 12th cycle: 6 From 13th cycle: 4	76.0	€ 7,600
Elotuzumab in combination with lenalidomide and dexamethasone					
Elotuzumab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	1st - 2nd cycle: 4 From 3rd cycle: 2	30.0	€ 3,000
Elotuzumab in combination with pomalidomide and dexamethasone					
Elotuzumab	Surcharge for the preparation of a parenteral solution containing monoclonal antibodies	€ 100	1st - 2nd cycle: 4 From 3rd cycle: 1	19.0	€ 1,900
Daratumumab in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	4	32.0	€ 3,200
Daratumumab in combination with carfilzomib and dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	6	78.0	€ 7,800

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
Isatuximab in combination with carfilzomib and dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	6	78.0	€ 7,800
Pomalidomide in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1st - 8th cycle: 4 From 9th cycle: 2	50.8	€ 5,080
Panobinostat in combination with bortezomib and dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1st - 8th cycle: 4 9th – 16th cycle: 2	32 – 48	€ 3,200 – € 4,800
Carfilzomib in combination with dexamethasone					
Carfilzomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	6	78.0	€ 7,800
Bortezomib in combination with pegylated liposomal doxorubicin					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	4	32.0	€ 3,200
Doxorubicin (pegylated, liposomal)	Surcharge for production of a parenteral preparation	€ 100	1	8.0	€ 800

Courtesy translation – only the German version is legally binding.

Designation of the therapy	Type of service	Costs/ unit	Number/ cycle	Number/ patient/ year	Costs/ patient/ year
	containing cytostatic agents				
Bortezomib in combination with dexamethasone					
Bortezomib	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	4	16.0 – 32.0	€ 1,600 – € 3,200
Cyclophosphamide as monotherapy					
Cyclophosphamide	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	13.0 – 365.0	€ 1,300 – € 36,500
Melphalan as monotherapy					
Melphalan	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	13.0	€ 1,300
Melphalan in combination with prednisolone or prednisone					
Melphalan	Surcharge for production of a parenteral preparation containing cytostatic agents	€ 100	1	8.7 – 13.0	€ 870 – € 1,300

Courtesy translation – only the German version is legally binding.

II. The resolution will enter into force on the day of its publication on the GBA website on 1 October 2026.

The justification for this resolution will be published on the GBA website at www.g-ba.de.

Berlin, 1 October 2026

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Dr Optendrenk

Courtesy translation – only the German version is legally binding.